A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Kai Qu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants…. Hauptthemen laut MEDLINE: Atherosclerosis, Macrophages, Reactive Oxygen Species, Lipid Metabolism. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Postdoctoral Research Foundation of China, Fundamental Research Funds for Central Universities.
Abstract (Originalsprache)
Atherosclerosis (AS) management typically relies on therapeutic drug interventions, but these strategies typically have drawbacks, including poor site specificity, high systemic intake, and undesired side effects. The field of cell membrane camouflaged biomimetic nanomedicine offers the potential to address these challenges thanks to its ability to mimic the natural properties of cell membranes that enable enhanced biocompatibility, prolonged blood circulation, targeted drug delivery, and evasion of immune recognition, ultimately leading to improved therapeutic outcomes and reduced side effects. In this study, a novel biomimetic approach is developed to construct the M1 macrophage membrane‐coated nanoprodrug (MM@CD‐PBA‐RVT) for AS management. The advanced MM@CD‐PBA‐RVT nanotherapeutics are proved to be effective in inhibiting macrophage phagocytosis and facilitating the cargo delivery to the activated endothelial cells of AS lesion both in vitro and in vivo. Over the 30‐day period of nanotherapy, MM@CD‐PBA‐RVT is capable of significantly inhibiting the progression of AS, while also maintaining a favorable safety profile. In conclusion, the biomimetic MM@CD‐PBA‐RVT shows promise as feasible drug delivery systems for safe and effective anti‐AS applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants Bioengineering College of Chongqing University, Chongqing, 400030, Ch…
- Chongqing Municipality Clinical Research Center for Endocrinology and Metabolic Diseases, Chongqing University Three Gorges Hospital, Chongqing, 404000, China.
- Jin Feng Laboratory Chongqing, Chongqing, 401329, China.
ORCID-Profile: Wei Wu
Förderung
- National Natural Science Foundation of China
- Postdoctoral Research Foundation of China
- Fundamental Research Funds for Central Universities
Zitieren
APA
Qu, K., Zhong, Y., Zhu, L., Mou, N., Cao, Y., Liu, J., Wu, S., Yan, M., Yan, F., Li, J., Zhang, C., Wu, G., Zhang, K., Qin, X., & Wu, W. (2024). A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401113
Vancouver
Qu K, Zhong Y, Zhu L, Mou N, Cao Y, Liu J, et al. A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401113
BibTeX
@article{Qu2024,
author = {Qu, Kai and Zhong, Yuan and Zhu, Li and Mou, Nianlian and Cao, Yu and Liu, Jie and Wu, Shuai and Yan, Meng and Yan, Fei and Li, Jiawei and Zhang, Cheng and Wu, Guicheng and Zhang, Kun and Qin, Xian and Wu, Wei},
title = {A Macrophage Membrane‐Functionalized, Reactive Oxygen Species‐Activatable Nanoprodrug to Alleviate Inflammation and Improve the Lipid Metabolism for Atherosclerosis Management},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401113}
}
EUVIMED